Key Highlights
- Shares rose 2.47% in today's session to around $400, nearing the stock's 52-week high.
- The FDA granted Breakthrough Device designation to Natera's multi-cancer early detection blood test, a status meant to speed up regulatory review.
- The FDA reviewed data spanning 12 cancer types before granting the designation.
- Two research firms have raised their price targets on the stock ahead of the company's upcoming quarterly Earnings report.
Breakthrough Device Status Speeds Up the Regulatory Path
Natera (NASDAQ:NTRA) shares rose in today's session after the company announced that its multi-cancer early detection assay received Breakthrough Device designation from the FDA. The designation is intended for technologies that could offer meaningfully better diagnosis or treatment for life-threatening conditions, and it allows closer, faster collaboration with the agency during development.
Natera is a global leader in cell-free DNA testing and precision medicine, with products spanning oncology, women's health, and organ health. The multi-cancer assay analyzes fragments of DNA circulating in the blood to screen for multiple cancer types from a single sample.
Data Across 12 Cancer Types Supported the Designation
In granting the designation, the FDA assessed data covering 12 different cancer types, evaluating the test's sensitivity, specificity, and ability to identify the likely origin of a cancer signal. The company said the results were compelling enough to support Breakthrough Device status, though this designation does not represent full Marketing approval.
Company Leadership said the goal remains detecting cancer earlier, when treatment tends to be more effective, framing the designation as a meaningful step in a multi-year development effort.
Strong Growth Backdrop Ahead of Earnings
Natera carries a market Capitalization near $57 billion. The company's Revenue rose nearly 39% in its most recent reported quarter, with oncology testing volumes up more than 54% over the same period. Two research firms have raised their price targets on the stock in recent sessions, ahead of Natera's upcoming quarterly results.
Outlook: Full Approval Pathway Still Ahead
Breakthrough Device designation accelerates review timelines but does not guarantee approval, so investors will likely watch for further regulatory updates and additional clinical data as the multi-cancer test moves closer to a potential commercial launch.






Please wait processing your request...